<DOC>
	<DOC>NCT02260986</DOC>
	<brief_summary>The purpose is to demonstrate efficacy and long term safety of dupilumab in combination with topical corticosteroids in patients with moderate to severe AD.</brief_summary>
	<brief_title>Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Patients With Moderate-to-Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Key 1. Chronic atopic dermatitis (AD) that has been present for at least 3 years before the screening visit 2. Documented recent history (within 6 months before the screening visit) of inadequate response to a sufficient course of outpatient treatment with topical AD medication(s). Key 1. Participation in a prior dupilumab clinical trial 2. Important side effects of topical medication (eg, intolerance to treatment, hypersensitivity reactions, significant skin atrophy, systemic effects), as assessed by the investigator or treating physician 3. Having used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, is likely to require such treatment(s) during the first 2 weeks of study treatment: 1. Immunosuppressive/immunomodulating drugs (eg, systemic steroids, cyclosporine, mycophenolatemofetil, Janus kinase inhibitors, IFNÎ³, azathioprine, methotrexate, etc) 2. Phototherapy for AD 4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit 5. History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening 6. Positive hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody at the screening visit 7. Active or acute infection requiring systemic treatment within 2 weeks before baseline visit 8. Known or suspected history of immunosuppression 9. Pregnant or breastfeeding women, or planning to become pregnant or breastfeed during the patient's participation in this study Note: The eligibility criteria listed above is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial therefore not all inclusion/ exclusion criteria are listed.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>